Bajaj Healthcare announced that the Board of Directors of the Company at its meeting held on 24 May 2024, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 20%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net loss of Bajaj Healthcare reported to Rs 29.92 crore in the quarter ended March 2024 as against net profit of Rs 3.59 crore during the previous quarter ended March 2023. Sales declined 13.11% to Rs 133.90 crore in the quarter ended March 2024 as against Rs 154.11 crore during the previous quarter ended March 2023.For the full year,net loss reported to Rs 83.79 crore in the year ended March 2024 as against net profit of Rs 43.02 crore during the previous year ended March 2023. Sales declined 26.69% to Rs 473.42 crore in the year ended March 2024 as against Rs 645.80 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales133.90154.11 -13 473.42645.80 -27 OPM %11.9814.29 -16.1117.24 - PBDT16.4816.77 -2 55.2795.39 -42 PBT9.1812.08 -24 27.6578.18 -65 NP-29.923.59 PL -83.7943.02 PL Powered by Capital Market - Live News

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 24 May 2024Powered by Capital Market - Live News

Bajaj Healthcare (BHL) announced that it has entered into a definitive CDMO agreement with esteemed UK/EU based customers for the supply of 15 Active Pharmaceutical Ingredient (APIs). Under this agreement, BHL will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent. The CDMO agreement will be executed through its in-house R&D and manufacturing capacities at Savli Vadodara, Gujarat.Powered by Capital Market - Live News

Net loss of Bajaj Healthcare reported to Rs 2.20 crore in the quarter ended December 2023 as against net profit of Rs 11.05 crore during the previous quarter ended December 2022. Sales declined 18.10% to Rs 108.57 crore in the quarter ended December 2023 as against Rs 132.57 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales108.57132.57 -18 OPM %17.9822.96 - PBDT13.6725.14 -46 PBT6.3220.71 -69 NP-2.2011.05 PL Powered by Capital Market - Live News